Accessibility Menu
Imagion Biosystems logo

Imagion Biosystems(ASX) IBX

Market CapA$5.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-31%
1 Month+0%
A$0.01
-15.38%
-0.00Today
Imagion Biosystems last closing stock price
MetricPriceDate
Last closeAUD 0.012026-08-14
Imagion Biosystems stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.38%AUD 0.012026-08-07
1 month+0%AUD 0.012026-07-15
3 month-21.43%AUD 0.012026-05-15
Year to date-56%AUD 0.032025-12-31
1 year-31.25%AUD 0.022025-08-14
3 year-98.28%AUD 0.642023-08-15
5 year-99.67%AUD 3.322021-08-13
Since inception-99.79%AUD 5.362017-06-22

Imagion Biosystems Financials at a Glance

Market Cap

A$5.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.69M

Net Income (TTM)

-A$6.38M

EPS (TTM)

-A$0.02

P/E Ratio

-0.71

Dividend

A$0.00

Beta (Volatility)

-0.13 (Low)

Price

A$0.01

Volume

4,970,700

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.06

Estimated Earnings Date

Feb 26, 2026

IBX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imagion Biosystems

Imagion Biosystems Limited is a medical imaging company focused on developing innovative technologies for cancer detection using bio-safe magnetic nanoparticles. The company operates in the fields of nanotechnology, biotechnology, and medical imaging, with a commitment to advancing cancer diagnostics.

Products and Services
  • MagSense: A Phase 2 imaging agent for HER2 breast cancers
  • PrecisionMRX: An iron oxide nanoparticle for magnetic relaxometry
  • Collaboration with Wayne State University for optimized MRI sequences
Growth Outlook
  • Advancements in MagSense could enhance cancer detection capabilities
  • Ongoing research for prostate and ovarian cancer diagnostics
  • Potential market expansion through strategic collaborations
Financial Highlights
  • Recent quarterly revenue of AUD 0, indicating ongoing development phase
  • Trailing twelve months (TTM) net income of AUD -2.65 million
  • Cash and cash equivalents increased to AUD 1.85 million in Q4 2025
Imagion Biosystems Limited is positioned in a niche market with significant growth potential, particularly in cancer diagnostics. The company's focus on innovative imaging technologies, such as MagSense, aims to improve early detection and treatment outcomes for various cancers. Despite current financial challenges, including negative net income and ongoing research and development expenses, the increase in cash reserves suggests a commitment to advancing its product offerings. The collaboration with Wayne State University further enhances the company's research capabilities, potentially leading to breakthroughs in medical imaging. Investors may find interest in the company's long-term vision and its efforts to carve out a significant presence in the healthcare sector.
AI Generated • Jul 23, 2026

Industry

Healthcare Equipment and Supplies

CEO

Isaac J. Bright, MD, MBA

Headquarters

Melbourne, VIC 3000, AU

IBX Financials

Key Financial Metrics (TTM)

Gross Margin

-2293.56%

Operating Margin

-16189.90%

Net Income Margin

-16746.15%

Return on Equity

142.99%

Return on Capital

-890.72%

Return on Assets

-210.82%

Earnings Yield

-1.41%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$5.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

539.94M

Volume

4.97M

Avg. Volume

2.74M

Financials (TTM)

Gross Profit

A$1.67M

Operating Income

-A$4.92M

EBITDA

-A$3.91M

Operating Cash Flow

-A$5.31M

Capital Expenditure

A$7.00

Free Cash Flow

-A$5.31M

Cash & ST Invst.

A$1.85M

Total Debt

A$2.56M

Imagion Biosystems Performance Analysis

Imagion Biosystems annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 473,429103.3%
20232023-12-31AUD 1,082,937128.7%
20242024-12-31AUD 1,160,2117.1%
20252025-12-31AUD 0N/A
Imagion Biosystems sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30119.0%
Q42024-12-31-37.0%
Q22025-06-30-97.5%
Q42025-12-31-100.0%
Imagion Biosystems annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.3552.2%
20232023-12-31AUD -0.4116.9%
20242024-12-31AUD -0.05-88.8%
20252025-12-31AUD -0.02-66.3%
Imagion Biosystems sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3068.8%
Q42024-12-3179.9%
Q22025-06-3011.7%
Q42025-12-3112.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$4.37K

+99.4%

Gross Margin

0.00%

N/A

Market Cap

A$5.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$539.94K

N/A

Employees

11

N/A

Net Income

-A$2.65M

+44.7%

EBITDA

-A$2.40M

+65.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

A$1.85M

+713.6%

Total Debt

A$2.56M

-57.5%

Accounts Receivable

A$34.20K

-53.6%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$2.56M

-8.3%

Return on Assets

-2.11%

N/A

Return on Invested Capital

1.93%

N/A

Free Cash Flow

-A$2.27M

+8.0%

Operating Cash Flow

-A$2.27M

+1.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACR.AXAcrux Limited
A$0.01+0.00%
HIQ.AXHITIQ Limited
A$0.01+0.00%
ZLD.AXZelira Therapeutics Limited
A$0.50+0.00%
IVX.AXInvion Limited
A$0.04+2.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About IBX

What is the current price of Imagion Biosystems?

Imagion Biosystems is trading at A$0.01 per share.

What is the 52-week range for Imagion Biosystems?

Over the past 52 weeks, Imagion Biosystems has traded between A$0.01 and A$0.06.

How much debt does Imagion Biosystems have?

As of the most recent reporting period, Imagion Biosystems reported total debt of A$2.56M.

How much cash does Imagion Biosystems have on hand?

Imagion Biosystems reported A$1.85M in cash and cash equivalents in its most recent financial results.

What is Imagion Biosystems’s dividend yield?

Imagion Biosystems does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.